Vaginal Progesterone to Prevent Spontaneous Preterm Birth in Women With a Sonographic Short Cervix: The Story of the PREGNANT Trial-Reference-Cited by-同舟云学术

Vaginal Progesterone to Prevent Spontaneous Preterm Birth in Women With a Sonographic Short Cervix: The Story of the PREGNANT Trial

Published:2024-04-05 Issue: Volume: Page:
ISSN:0009-9201
Container-title:Clinical Obstetrics & Gynecology
language:en
Short-container-title:

Author:

Romero Roberto¹²³,Meyyazhagan Arun¹⁴⁵,Hassan Sonia S.⁴⁶⁷,Creasy George W.⁸,Conde-Agudelo Agustin⁹

Affiliation:

1. Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland

2. Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan

3. Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan

4. Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan

5. Centre of Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy

6. Office of Women’s Health, Integrative Biosciences Center, Wayne State University, Detroit, Michigan

7. Department of Physiology, Wayne State University School of Medicine, Detroit, Michigan

8. Center for Biomedical Research, Population Council, New York, New York

9. Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, UK

Abstract

The PREGNANT trial was a randomized, placebo-controlled, multicenter trial designed to determine the efficacy and safety of vaginal progesterone (VP) to reduce the risk of birth <33 weeks and of neonatal complications in women with a sonographic short cervix (10 to 20 mm) in the mid-trimester (19 to 23 6/7 wk). Patients allocated to receive VP had a 45% lower rate of preterm birth (8.9% vs 16.1%; relative risk = 0.55; 95% CI: 0.33-0.92). Neonates born to mothers allocated to VP had a 60% reduction in the rate of respiratory distress syndrome. This article reviews the background, design, execution, interpretation, and impact of the PREGNANT Trial.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference144 articles.

1. Prevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment;Romero;Ultrasound Obstet Gynecol,2007

2. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial;Hassan;Ultrasound Obstet Gynecol,2011

3. Crystalline progestin;Allen;Science,1934

4. Nomenclature of corpus luteum hormone;Allen;Science,1935

5. Ludwig Fraenkel, corpus luteum and discovery of progesterone;Frobenius;Zentralbl Gynakol,1998

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Respect for history: an important dimension of contemporary obstetrics & gynecology;Journal of Perinatal Medicine;2024-09-16

2. Neonatal Outcomes after Maternal Biomarker-Guided Preterm Birth Intervention: The AVERT PRETERM Trial;Diagnostics;2024-07-09